Santhera To Snap Up Second DMD Drug As Idorsia Climbs Aboard
Executive Summary
Actelion spin-off Idorsia is becoming the largest shareholder in Santhera after deciding its fellow Switzerland-based group is best placed to advance its optioned DMD candidate vamorolone.
You may also be interested in...
Santhera Shores Up Finances With Chiesi Deal for Raxone
In a deal that could be worth CHF105m, the Swiss biotech has outlicensed Raxone to Chiesi for the rare eye disease LHON as it concentrates on the drug's filing for Duchenne muscular dystrophy.
Finance Watch: Relay Raises $400m – And It's Only The Third-Largest Biopharma VC Round Of 2018
The company isn't relaying any details about its drug targets, but will use the mega-round to take its first candidates into the clinic. Also, RiverVest raises a $184.4m VC fund, Annexon closes a $75m Series C, Takeda lists its stock in the US, and Aptorum goes public.
Deal Watch: Boehringer, Epizyme Team Up To Develop Epigenetic Cancer Therapies
BI and Epizyme’s collaboration will focus on developing novel cancer drugs targeting helicase and HAT enzyme dysregulation. MorphoSys and I-Mab will partner on developing an IO therapy targeting C5aR.